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http://dxObjective: Congenital heart valve disease is one of the most common abnormalities in children. There are limited
technological solutions available for treating children with congenital heart valve diseases. The aim of this study is
to provide the details of the consensus reached in terms of pediatric definitions, design approach, in vitro testing,
and clinical trials,whichmaybeused as guidance for developing prosthetic heart valves for the pediatric indication.
Methods: In stark contrast to the various designs of adult-sized replacement valves available in the market, there
are no Food and Drug Administration (FDA)–approved prosthetic heart valves available for use in the pediatric
population. There is a pressing need for FDA-approved pediatric valve devices in the United States. The
pediatric patient population has been typically excluded from replacement heart valve trials for several reasons.
In January 2010, heart valve manufacturers and pediatric clinicians collaborated with academicians and FDA
staff in a workshop to suggest ways to successfully evaluate pediatric prosthetic valves and conduct pediatric
clinical trials to provide acceptable heart valve replacement options for this patient population.
Results: Recommendations, derived from ISO 5840:2005 and the 2010 FDA Draft Replacement Heart Valve
Guidance, are provided for hydrodynamic, durability, and fatigue testing.
Conclusions: The article specifically addresses in vitro and premarket and postmarket approval clinical studies
that should be considered by a heart valve manufacturer for obtaining regulatory approval of pediatric sizes of
prosthetic heart valve designs that are already approved for adult clinical use. (J Thorac Cardiovasc Surg
2013;146:879-86)C
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DCongenital heart valve disease is one of the most common
malformations in children. Valve disease in children and
young adults can occur both on the systemic (commonly
left) side of the heart and on the pulmonary (commonly
right) side of the heart. Often, these valvular defects are
not isolated, but are associated with significant additional
structural defects, which may require extensive repair or
intervention. The most common valve abnormalities seen
in children include aortic stenosis, mitral stenosis, or regur-
gitation. Valvular regurgitation due to catheter-based or
surgical intervention aimed at treating severe stenosis is
the most common form of acquired valve defect in children
and can involve the aortic, mitral, and pulmonary valves.
Congenital tricuspid valve abnormalities are relatively
uncommon but can present a significant challenge to the
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The Journal of Thoracic and CaPulmonary (or right-sided) defects of the heart are most
often secondary to underdevelopment of portions or the
entire right ventricular outflow tract, including the
pulmonic valve. If severe, this can require placement of
a conduit that will facilitate blood flow from the patient’s
right ventricle to the pulmonary arteries. Unfortunately,
these conduits become dysfunctional rather quickly. There-
fore, patients with conduits are subjected to multiple
interventional and surgical procedures throughout their
lifetime. Congenital isolated pulmonic valve stenosis can
sometimes be treated percutaneously with balloon valvulo-
plasty. This technique, however, carries a risk that the
treated valve will later become regurgitant and require
surgical intervention. Defects involving the right-sided
atrioventricular valve, most commonly the tricuspid valve,
are fortunately rare and include Ebstein anomaly. Repair
and replacement of this valve continue to be significantly
challenging.
Managing patients with systemic, left-sided, congenital
heart valve disease, including aortic stenosis and mitral
valve stenosis or prolapse (also pediatric rheumatic fever
in developing countries), poses significant challenges for
physicians. There are limited technological solutions
available for these patients. Commercial bioprosthetic
valves for aortic and mitral valve replacement may not be
available in sizes that are appropriate for infants and
children. Few replacement heart valves are indicated for
pediatric patients.rdiovascular Surgery c Volume 146, Number 4 879
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
AWT ¼ accelerated wear testing
DFM ¼ dynamic failure mode
EOA ¼ effective orifice area
FDA ¼ Food and Drug Administration
HVG ¼ heart valve guidance
ISO ¼ International Standards Organization
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DFigure 1 shows the distribution of valve procedures
performed at Children’s Hospital Boston (Boston, Mass)
during a 5-year period (2005-2010). Most of the procedures
performed involve reconstruction of the native valve, often
with the use of autologous or xenograft material, despite
the fact that most valve repair operations in children are
palliative and will require further reconstruction or,
ultimately, replacement.
The clinical impact of congenitally deformed valves is
significant and often lifelong. Treatment decisions are
almost always affected by the effects of rapid somatic
growth, active lifestyle, and accelerated deterioration of
biological prostheses.
Furthermore, pediatric valve replacement is a high-risk
procedure with higher operative mortality, reoperation rate,
and late morbidity compared with adult patients undergoing
the same operation. The reasons for the higher operative
mortality aremultiple and complex.Most often, the available
prosthesis is too large for the child’s anatomy, resulting in
delay in referral for surgery, and when surgery is undertaken,
additional steps are often required to enlarge the site of
implantation to accommodate the prosthesis. These enlarge-
ment procedures carry additional risk of injury to adjacent
structures, such as specialized cardiac conduction tissue,
coronary arteries, and atrial and interventricular septa.
An example of the early and late outcomes of aortic valve
replacement (AVR) in children is provided in the study
by Karamlou and colleagues,1 in which they performed
competing risk analysis of 2 mutually exclusive risk factors
after AVR, death, and prosthesis replacement in 160
children. The authors analyzed the use of mechanical valves
and bioprosthetic valves. Of 185 total AVR episodes in
which a type of the implanted valve was documented,
mechanical valves were implanted in 94 patients (Bjork-
Shiley, St Jude Medical, Carbomedics, and others). The
authors’ analysis showed that, after 10 years from initial
AVR, 19% of patients had died without a second AVR,
34% underwent a second AVR, and only 47% remained
alive without repeated replacement (Figure 2).
Similar results have been reported for mitral valve
replacement in children with operative mortality ranging
from 4% to 7.4%, approximately double that reported for
similar procedures in adults. The long-term results also880 The Journal of Thoracic and Cardiovascular Surgindicate a continuing risk of death or need for reoperation
for valve re-replacement (Figure 3).
AVAILABLE VALVE PROSTHESES FOR
PEDIATRIC USE
Although there are many types of replacement heart
valves available on the market for adult patients, the same
is not true for pediatric patients. Clinical studies have
routinely been conducted on the adult patient population,
excluding pediatrics. The pediatric patient population has
been typically excluded from replacement heart valve trials
for several reasons, some of which include the following:
 Limited patient pool requiring a replacement heart
valve that can lead to prolonged recruitment to achieve
required enrollment numbers
 Complex health histories (of which many lead to early
mortality)
 Comorbidities can confound the adverse event profiles
for the study, making it difficult to assess the overall
safety of the valve
 Limited valve sizes available
 In addition, after valve replacement, the pediatric
patient continues to grow, ultimately necessitating
reoperation and the placement of a larger valve
 Uniformity of an identifiable patient population is
extremely challenging to achieve, again leading to
prolonged study recruitment
Collaboration Among Heart Valve Manufacturers,
Pediatric Clinicians, Academicians, and FDA
In 2008, the US Food and Drug Administration (FDA)
leadership contacted the heart valve industry to suggest
that FDA and industry might collaborate to develop
a least-burdensome approach to making pediatric heart
valves available in the marketplace. In January 2010, heart
valve manufacturers and pediatric clinicians collaborated
with academicians and FDA during a workshop to suggest
ways to successfully design and evaluate pediatric pros-
thetic valves and conduct pediatric clinical trials to provide
acceptable heart valve replacement options for this patient
population. Consensus was achieved with respect to the pe-
diatric definition, design philosophy, appropriate in vitro
testing,2 and criteria for conducting a clinical trial.3 This
article provides the details of the consensus reached, which
may be used as guidance for developing prosthetic heart
valves for a pediatric indication. This collaboration between
heart valve manufacturers, pediatric clinicians, academi-
cians, and the FDA would likely lead to increased availa-
bility of pediatric devices in other regulated regions.
Pediatric Patient Population
Pediatrics include neonates (newborns), infants, toddlers,
children, and adolescents. These subpopulations can beery c October 2013
FIGURE 1. Distribution of valve surgical procedures performed at 1 cen-
ter (Children’s Hospital Boston, Boston,Mass) over a 5-year period.CAVC,
Complete atrioventricular canal; AVC, atrioventricular canal.
FIGURE 3. Freedom from reoperation for patients having valves im-
planted in the atrioventricular position. Numbers under the curve indicate
patients at risk. CI, Confidence interval.
Yoganathan et al Congenital Heart Diseasedefined as shown in Table 1. The definitions are based on the
information provided in the June 2003 Pediatric Expertise
for Advisory Panels4 and recommendations from the
pediatric clinicians in attendance at the 2010 workshop.C
H
DPediatric Design Approach
The goal of the pediatric design approach is to provide
additional options for the treatment of these patients based
on known safety and effectiveness data of approved designs.
Because the pediatric patient’s heart valves are smaller than
those of the adult patient, a logical approach would be to
take a previously proven design and scale it down to fitFIGURE 2. Competing-risks depiction of events after initial aortic valve
replacement (AVR) in 160 children. All patients are represented in the graph
as alive at the initial AVR and thereafter migrate to 1 of 3 mutually exclu-
sive end states (death, subsequent AVR, or remaining alive without subse-
quent AVR) at a time-dependent rate defined by the underlying hazard
functions. At any point, the sum of the proportion of children in each state
is 100%.
The Journal of Thoracic and Cathe smaller pediatric patient. All valve components would
not necessarily be scaled linearly using a common factor,
because some structural support components may have to
be scaled differently from others to maintain a design and
stress envelope consistent with the adult sizes and
accommodating differing component material properties.
Fit-up and dimensional tolerances are other examples of
elements that may not scale linearly or in exact proportion
to other component geometries.
The pediatric valve would use the same materials, be
processed in the sameway, and have a demonstrably similar
geometry to a previously FDA-approved design. By using
this approach, one would be starting with an established
record of clinical safety and effectiveness, based on
a clinically proven design, materials, and processing. It is
anticipated that pediatric designs would typically involve
scaling down the smallest approved adult-sized valve in
a given design by 1 to 3 sizes. It is expected that the
potential risks of the new pediatric size(s) would, therefore,
be minimized, and that this rationale would allow for
reduced clinical study requirements for the new heart valve
sizes by leveraging existing safety and effectiveness data
from already FDA-approved adult prosthetic heart valves.
The following discussion of in vitro testing and clinical
trials is based on this philosophy.
In Vitro Data Required to Support a Premarket
Approval Application
The proposed engineering and testing paradigm for
pediatric replacement heart valves is based on International
Standards Organization (ISO) 5840:2005 (ISO 5840)5 and
the 2010 FDA Draft Replacement Heart Valve Guidance
(HVG).6 There is no significant reduction in the in vitro
testing from these historic adult valve norms. Similar tests,
sample sizes, and analyses are proposed as have been
used for the approval of the current designs. Specific rec-
ommendations are provided for hydrodynamic, durability,rdiovascular Surgery c Volume 146, Number 4 881
TABLE 1. Pediatric subpopulations
Pediatric
subpopulation
Approximate
age range Definition
Newborn Birth to 1 mo 0<Age<30 d
Infant 1 mo to 1 y 30 d  Age<1 y
Toddler 1-4 y 1 y  Age<5 y
Child 5-12 y 5 y  Age<13 y
Adolescent 13-21 y 13 y  Age<22 y
Congenital Heart Disease Yoganathan et al
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Dand fatigue testing. There are 2 main differences from the
proposed paradigm when compared with historic norms:
testing conditions and position within the heart (because
systemic and pulmonary pressures can differ significantly).
First, as patient age and size decrease, there is a substantial
increase in heart rate and systolic duration, coupled with
a substantial decrease in cardiac output. These conditions
vary with age and should be selected based on the target
pediatric subpopulation. Second, the testing is intended
to address both right- and left-sided heart valve replace-
ment, which are of equal interest and need. Therefore,
testing conditions and suggestions are provided for
pulmonic and tricuspid valves, as well as for aortic and
mitral valves.
Hydrodynamic testing. The ISO 5840 and HVG docu-
ments suggest that hydrodynamic tests be performed to
characterize the behavior of a prosthetic heart valve. The
recommended tests are provided in Table 2.
The specific recommended test conditions for the right
and left sides of the heart are provided in Tables 3 and 4
as a function of the pediatric subpopulation group. The
recommended values are based on handbook and literature
data.7-11TABLE 2. Hydrodynamic flow characterization tests
Test 1 Size down 2 Sizes down
Steady backflow leakage Recommended Recommended for
each size
Pulsatile flow pressure
decrease
Recommended Recommended for
each size
Pulsatile flow
regurgitation
Recommended Recommended for
each size
Flow visualization Recommended Recommended for
smallest size
Leaflet kinematic motion
analysis studies
Recommended Recommended for
each size
Cavitation potential Justification with
experimental fluid
mechanics and
computational fluid
dynamics
Justification with
experimental fluid
mechanics and
computational fluid
dynamics
Verification of Bernoulli
relationship
Justification with
experimental fluid
mechanics and
computational fluid
dynamics
New data for
smallest size
882 The Journal of Thoracic and Cardiovascular SurgThe hydrodynamic testing would be conducted as
described in ISO 5840, with the exception of the test
chamber diameter. Steady and pulsatile flow hydrodynamic
tests, flow visualization, cavitation potential, and Bernoulli
verification studies for pediatric-sized valves should be
conducted in test chambers of appropriate geometry and
size. Kinematic motion analysis studies should be conduc-
ted, demonstrating that the pediatric valve occluder moves
in a similar way to the adult valve occluder (ie, open and
close completely), under appropriate simulated physiolo-
gical conditions.
Overall structural performance testing. The ISO 5840
and HVG documents suggest that several general tests
and analyses be performed to characterize the structural
integrity of a prosthetic valve. These categories are listed
in Table 5.
AWT data. The ISO 5840 and HVG documents provide
guidance on how to perform accelerated wear testing
(AWT), or durability testing, to help characterize the
structural integrity of a prosthetic heart valve. Recommen-
dations for the specific pediatric AWT test conditions for
the right and left sides of the heart are provided in Table 6
as a function of the pediatric subpopulation group. The
recommended values are based on handbook and literature
data.7,8
Because children can quickly outgrow a replacement
heart valve, the duration for AWT testing has been adjusted
for the youngest subpopulations based on consideration of
the guidance documents and the consensus of theworkshop.
Recommendations for the specific pediatric AWT duration
are provided in Table 7 as a function of the pediatric
subpopulation group.
Stress and fatigue life analyses. As part of structural
performance characterization, the ISO 5840 and HVG
documents require stress and life analyses for a prosthetic
heart valve. The stress analysis typically requires input
data from test measurements of device loading over the
cardiac cycle. The fatigue life analysis typically requires
fatigue data run under various stress conditions and run
out to various numbers of cycles. The recommended test
conditions for determining device loading in the stress
analysis are provided in Table 8. Table 8 also provides
recommendations for the specific pediatric life analysis
loading test conditions, as well as the life criteria as
a function of the pediatric subpopulation group, based on
consideration of the guidance documents and the consensus
of the workshop participants.
As with all the in vitro tests, this approach to fatigue life
analysis only applies to an existing, approved design that is
scaled down to pediatric sizes, using identical materials.
There is no official FDA guidance for replacement heart
valves. Nevertheless, the draft 1994 Replacement HVG and
ISO 5840 provide useful information on approaches to
fatigue testing/life analysis. In addition, the methods usedery c October 2013
TABLE 3. Steady backpressure and steady forward flow test conditions
Pediatric subpopulation
Steady forward flow rates,
L/min
Left-sided heart steady
backpressure, mm Hg
Right-sided heart steady
backpressure, mm Hg
Newborn 1.5, 3, 5, 10 40, 80 5, 10, 20
Infant 3, 5, 10, 15 40, 80, 120 5, 10, 20
Toddler 5, 10, 15, 20 40, 80, 120 5, 10, 20
Child 5, 10, 15, 20, 25 40, 80, 120, 160 5, 10, 20, 30
Adolescent 5, 10, 15, 20, 25, 30 40, 80, 120, 160, 200 5, 10, 20, 30, 40
Yoganathan et al Congenital Heart Disease
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Dto previously qualify the adult sizes of a particular design
would also be appropriate to qualify the scaled pediatric
sizes of the same design.
To impart a significant degree of conservatism into the
analysis, the FDA has historically required that fatigue/
life analysis be applied to the ‘‘worst case,’’ or the single
most severe combination of all the factors that could
contribute to fatigue. If the worst-case valve size can be
shown to satisfy the fatigue life requirements, then all the
other sizes will also meet the fatigue life requirements.
Approved designs that have previously identified the
worst-case size and ‘‘passed’’ a rigorous life analysis can
be scaled down to pediatric sizes, using identical materials.
In this situation, it will be necessary to carefully perform
a thorough stress analysis on each of the new pediatric sizes,
based on new loading and/or deflection measurements of
the new sizes. If the new stress analysis shows that the
pediatric sizes are no worse than the previously identified
worst case, then the pediatric size may also be considered
to pass the life analysis.
Specifically, given a thorough damage-tolerant fatigue
analysis based on material specimen testing and analysis,
the previous material testing would apply and a new stress
analysis showing that the pediatric sizes are not the worst
case could be used to justify no additional damage-tolerant
fatigue testing. Similarly, given a thorough stress/life fatigue
analysis based onmaterial specimen testing and analysis, the
previous material testing would apply and a stress analysis
showing that the pediatric sizes are not the worst case could
be used to justify no additional stress/life fatigue testing.
Finally, as long as a thorough stress analysis was performed
on the adult sizes and the pediatric sizes, a similar
justification could apply to the component testing approach.
However, if component testing was previously performedTABLE 4. Pulsatile flow test conditions
Pediatric
subpopulation
Systolic
duration,%
Beat rate,
beats/min
Car
Newborn 50 60, 150, 200 0.3
Infant 50 60, 120, 200 0
Toddler 45 60, 100, 160 1
Child 40 60, 80, 140
Adolescent 35 45, 70, 120
MAP, Mean arterial pressure.
The Journal of Thoracic and Cafor the adult sizes without a thorough stress analysis, then
this justification would not apply.
DFM testing. TheHVGdocument suggests that a selection
of valves be tested to failure after AWT testing to determine
the method in which the prosthetic heart valve will fail. If
the stress analysis demonstrates that the new size is not
the worst case, and if dynamic failure mode (DFM) testing
will have already been performed for the larger sizes of
the valve, it may be reasonable to forego additional DFM
testing based on a scientifically valid justification.
If the new size(s) prove(s) to be the newworst case, it may
be reasonable to perform DFM testing on non-AWT tested
valves, based on a scientifically valid justification. In this
situation, this ‘‘non-AWT DFM’’ is reasonable because
the chief benefit of the test, for both tissue valves and
mechanical valves, is from comparing the test valve with
the reference valves when both have a known clinical beha-
vior and a knownDFMbehavior. The damage caused during
a normal AWT is typically insignificant compared with the
damage caused by the extreme conditions used for a DFM.
For the pediatric scenarios, it is assumed that approved
designs, which have previously qualified using the full array
of FDA and ISO 5840 tests, will be scaled down to pediatric
sizes, using identical materials. Because failure modes
in the DFM are controlled by design, materials, and the
pressure in the DFM, it is unlikely that new failure modes
would be observed in this situation.
If new failure modes are observed in the pediatric size
using a non-AWT DFM test, it should be required to run
a standard AWT-DFM as a check against any unintended
consequences from the design scaling.
Sewing ring integrity testing. The ISO 5840 and HVG
documents suggest testing the sewing ring to demonstrate
that the sewing ring will not become separated from thediac output,
L/min
Left-sided heart
MAP, mm Hg
Right-sided
heart MAP, mm Hg
, 0.5, 1, 1.5 45 20
.5, 1, 2, 3 55 20
.5, 3, 4.5 65 20
2, 3.5, 5 80 20
2, 5, 7 100 20
rdiovascular Surgery c Volume 146, Number 4 883
TABLE 5. Structural performance characterization
Test 1 Size down 2 Sizes down
AWT Table 7 recommendations at subpopulation pressures Table 7 recommendations at subpopulation pressures
Stress and fatigue life analyses Perform FEA for new size: perform life analysis on
worst-case size for entire combined adult/pediatric
size range
Perform FEA for new sizes: perform life analysis on
worst-case size for entire combined adult/pediatric
size range
Dynamic failure Mode test Test worst-case size only, not necessarily after AWT
(justification required)
Test worst-case size only, not necessarily after AWT
(justification required)
Sewing ring integrity testing Test Test all sizes
Design-specific testing Test Test all sizes
AWT, Accelerated wear testing; FEA, finite element analysis.
Congenital Heart Disease Yoganathan et al
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Dprosthetic heart valve, and that the ring will retain sutures
under worst-case loading. This same testing is appropriate
for pediatric sizes.
Design-specific testing. The ISO 5840 and HVG docu-
ments suggest performing additional appropriate design-
specific testing, based on the nature of the prosthetic valve
under consideration. The same design-specific testing
previously performed on the adult sizes of the approved
design is appropriate for the pediatric sizes.
Other Categories of In Vitro Data to Support
a Premarket Approval Supplement Application
For the information categories of sterilization validation,
shelf-life testing, biocompatibility evaluation, microbiologi-
cal testing, corrosion testing, and large-animal invivo testing,
it is reasonable to apply justifications based on previous test-
ing for the adult sizes. The justifications would be based on
using the same materials processed using the same methods
and a scaled design from a previously approved adult valve.
Revisions to ISO 5840 and the HVG
This white paper uses testing described in ISO 5840:2005
and the 2010 FDA Draft Replacement HVG. From time to
time, ISO standards are updated, and the HVG may at
some time be finalized. If either or both of these cases occur,
then the recommendations in this white paper will require
consideration, on a case-by-case basis, depending on
changes that might be applicable. However, because the
pediatric heart valves addressed by this white paper are
down-sized versions of valves previously approved for
adults using ISO 5840 and the HVG, ongoing use of the
2005 and 2010 documents may continue to be appropriate.TABLE 6. Minimum values for AWT peak differential pressure
Pediatric
subpopulation
Minimum peak differential pressure, mm Hg
Mitral Aortic Tricuspid Pulmonary
Newborn 75 50 30 10
Infant 90 60 30 10
Toddler 97 67 30 10
Child 105 75 30 10
Adolescent 120 90 30 10
AWT, Accelerated wear testing.
884 The Journal of Thoracic and Cardiovascular SurgCLINICAL DATA REQUIRED TO SUPPORT
A PREMARKETAPPROVAL APPLICATION
Rationale for Establishing the Clinical Benefit of
a New Pediatric Replacement Heart Valve
The safety and effectiveness of a new heart valve
replacement are clinically evaluated by 3 basic perfor-
mance parameters, including hemodynamics, durability,
and adverse event rates. During IDE* clinical trials,
significant clinical data are collected to demonstrate
clinical safety and effectiveness of a new heart valve de-
sign through adverse event and hemodynamic analysis,
respectively. However, it is difficult to assess long-term
valve durability based on the overall follow-up time during
the IDE study.
As noted, pediatric heart valve replacement studies are
difficult to conduct because of the smaller pediatric patient
pool compared with the adult patient pool. Therefore, to
mitigate this difficulty, a logical approach would be to
design a smaller pediatric valve using the same materials,
scaled down from a previously FDA-approved adult heart
valve replacement design. By using this approach, a manu-
facturer would start with a proven record of clinical safety
and effectiveness with the current heart valve replacement
device. Because the pediatric valve design would be based
on a clinically proven adult design with clinically proven
materials, collected data would be focused on the use of
the proven design in the pediatric patient population.Pediatric Clinical Trial Design
The focus of an IDE pediatric clinical trial should be
similar to standard IDE trials (assessing clinical safety
and effectiveness). If a clinically proven design was
selected, valve durability would already be established.
Although new valve designs are outside the scope of this
white paper, if a new valve design was selected, valve
durability would need to be assessed (eg, in vitro and
premarket and postmarket studies).
Clinical safety data and study design for the pediatric
population should be focused on valve-related adverse* Investigational Device Exemption (IDE), described in 21 CFR Part 12, Investiga-
tional Device Exemptions.
ery c October 2013
TABLE 7. Pediatric AWT test duration recommendations
Pediatric subpopulation
Life analysis cycle criterion
(equivalent years)
FEA peak differential pressure/cardiac output, mm Hg/L/min
Left side of the heart Right side of the heart
Newborn 5 90/1.5 40/1.5
Infant 7 100/3 40/3
Toddler 10 110/4.5 40/4.5
Child 15 135/5 40/5
Adolescent 15 160/7 40/7
AWT, Accelerated wear testing; FEA, finite element analysis.
TABLE 8. Pediatric FEA loading and life analysis recommendations
Pediatric
subpopulation
Mechanical valves
(equivalent years)
Tissue valves
(equivalent years)
Yoganathan et al Congenital Heart Disease
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Devent rates because there may be other comorbidities
that could confound the adverse event profiles for the
study. The preferred approach for collection of clinical
data is a prospective clinical trial design. However,
many clinical studies have been successfully completed
with retrospective data. Because the pediatric patient
population for heart valve dysfunction is somewhat lim-
ited, it may make sense to consider evaluation of retro-
spective clinical data or data from peer-reviewed
published journals.
Methods of assessing hemodynamic parameters (eg, ef-
fective orifice area [EOA], EOA index, cardiac output,
and cardiac index) in the pediatric population may differ
from those in the adult population. For example, cardiac
output and cardiac index are not routinely calculated in chil-
dren. In addition, small errors in measuring the left ventric-
ular outflow tract diameter lead to propagation of error in
EOA calculation, and these larger errors are amplified in
children when compared with the relatively small pediatric
annulus dimensions. Hence, native valve area and prosthetic
valve EOA calculation with the continuity equation are not
commonly used in children,12 and new techniques for pros-
thetic valve evaluation (eg, 3-dimensional echo with
planimetry and ejection fraction) are evolving. Therefore,
the sponsor will have to work closely with the FDA to de-
termine the appropriate hemodynamic assessments and
techniques for the device and pediatric population under
consideration.
For valve designs that are already clinically proved, the
clinical data would be collected from at least 3 centers
with data available on a minimum of 15 patients per valve
size who have reached a minimum of 1 year of follow-up.
The follow-up time points would be based on the standard
of care (ie, within 30 days, 6 months, 1 year, and annually
thereafter until the study ends). The proposed preoperative,
operative, and postoperative data collected are described in
Table 9. Long-term postapproval data may also be needed,
as described later.Newborn 5 2
Infant 7 5
Toddler 10 5
Child 15 5
Adolescent 15 5
FEA, Finite element analysis.Postmarket Clinical Data Requirements
After market approval, the pediatric IDE patients should
be observed in a postapproval study for a minimum of
5 years (or less if the valve is removed earlier). SponsorsThe Journal of Thoracic and Cashould consider consent to the IDE cohort for more than
5 years to allow transition to the postapproval study with
ease. After appropriate follow-up in the postapproval study,
‘‘conversion’’ to a sponsor registry follow-up would allow
these patients to be observed long-term after heart valve
replacement.
Additional postmarket data may also be collected beyond
the IDE cohort. This collection could involve additional
patient enrollment into the postapproval study, the sponsor
registry, or, alternatively, a national registry. A national
registry could be used to collect safety and effectiveness
data across multiple sponsors with FDA-approved pediatric
replacement heart valves. An example of such is the
Congenital Cardiac Surgery Database maintained by the
Society of Thoracic Surgeons.Summary
There is a clear and urgent need for FDA-approved
pediatric prosthetic heart valve devices in the United
States. The example set by FDA leadership would likely
lead to increased availability of pediatric devices in other
regulated economies. An ‘‘orphan category’’ for such de-
vices is an untenable scenario in the 21st century. This
white paper addresses important preclinical and premarket
and postmarket clinical studies that should be considered
by a heart valve manufacturer for obtaining regulatory ap-
proval of pediatric sizes of prosthetic heart valve designs
already approved for adult clinical use. It is hoped that
such a least-burdensome approach would lead to the ap-
proval of pediatric-sized mechanical and bioprosthetic
valves in the next few years. This paradigm could be ex-
tended to other cardiovascular devices with pediatric
applications.rdiovascular Surgery c Volume 146, Number 4 885
TABLE 9. Clinical study data for pediatric heart valves
Preoperative Operative Postoperative
Diagnosis Concomitant procedures Date of follow-up
Patient age/sex Patient age Patient age
Height/weight/body surface area Height/weight/body surface area Height/weight/body surface area
Previous cardiovascular procedures Date of implant Core laboratory–evaluated echocardiographic
hemodynamic data*
Comorbidities (known genetic syndromes and major
noncardiac diseases)
Implant position Anticoagulant/antiplatelet regimen
Type of valvular lesion (ie, stenosis, regurgitation, or
mixed stenosis/regurgitation)
Valve-related adverse events Valve-related adverse events
Cause of valvular lesion (eg, calcification/
degeneration, congenital, rheumatic, or infectious)
NYHA functional classification, if study patients are
adolescent and such data are available. For infants
and toddlers, Ross Scale functional classification
should be provided if available.y
NYHA functional classification, if study patients are
adolescent patients and such data are available. For
infants and toddlers, Ross Scale functional
classification should be provided if available.y
Blood collection specific to hemolysis
Spot urine urobilinogen collection may be used in
place of blood collection for hemolysis evaluation
for pediatric populations
NYHA, New York Heart Association. *For aortic and mitral valve replacement patients: peak gradient, mean gradient, performance index, valvular regurgitation, and ejection or
shortening fraction. Effective orifice area and effective orifice area index should be considered. For pulmonic and tricuspid valve replacement patients: peak gradient, mean
gradient, and valvular regurgitation. yData from Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol.
1992;13:72-5.
Congenital Heart Disease Yoganathan et al
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